The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A multicenter, randomized, phase 2, investigator-initiated ETCTN trial of olaparib + radium-223 vs. radium-223 in men with castration-resistant prostate cancer (CRPC) with bone metastases (BM) (COMRADE): Initial efficacy and biomarker analysis.
 
Rana McKay
Consulting or Advisory Role - Ambrx; Arcus Biosciences; Astellas Medivation; AstraZeneca; AVEO; Bayer; Blue Earth Diagnostics; Bristol Myers Squibb; Calithera Biosciences; Caris Life Sciences; Daiichi Sankyo; Dendreon; Esiai; Exelixis; Janssen; Lilly; Merck; Myovant Sciences; NeoMorph; Novartis; Pfizer; Sanofi; Seagen; Sorrento Therapeutics; Sumitomo Pharma Oncology; Telix Pharmaceuticals; Tempus; Vividion Therapeutics
Research Funding - Artera (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol Myers Squibb (Inst); Exelixis (Inst); Oncternal Therapeutics (Inst); Tempus (Inst)
 
Wanling Xie
Consulting or Advisory Role - Convergent Therapeutics; Prostate Cancer Clinical Trial Consortium
 
Archana Ajmera
Honoraria - NCCN
Consulting or Advisory Role - Astellas Pharma; Eisai; Nexus Pharmaceuticals Inc
 
Christina Jamieson
No Relationships to Disclose
 
Arlene Araneta
No Relationships to Disclose
 
Edmund Folefac
No Relationships to Disclose
 
Arif Hussain
No Relationships to Disclose
 
Christos Kyriakopoulos
Employment - Epic Systems (I)
Stock and Other Ownership Interests - Biogen; Epic Systems (I)
Consulting or Advisory Role - AVEO; EMD Serono; Exelixis; Janssen Oncology; Pfizer; Sanofi
Research Funding - AstraZeneca; Bristol Myers Squibb Foundation (Inst); EMD Serono (Inst); ESSA; Gilead Sciences; Madison Vaccines, Inc. (Inst); Pionyr; Sanofi
 
Adam Olson
Consulting or Advisory Role - RenovoRx
Research Funding - Varian Medical Systems
Travel, Accommodations, Expenses - Bioprotect
 
Mamta Parikh
Consulting or Advisory Role - Bicycle Therapeutics; Bristol Myers Squibb; Exelixis; Pfizer; Pfizer-Myovant; Sanofi/Aventis; Totus Medicines
Research Funding - Gilead Sciences; Karyopharm Therapeutics (Inst)
 
Rahul Parikh
No Relationships to Disclose
 
Biren Saraiya
Research Funding - Hookipa Pharma (Inst); Merck (Inst); OncoC4 (Inst); Regeneron (Inst)
 
Lincoln Pasquina
Employment - Foundation Medicine
Stock and Other Ownership Interests - Roche
Travel, Accommodations, Expenses - Foundation Medicine
 
Sarah Clifford
Employment - Foundation Medicine
 
Merrida Childress
Employment - Foundation Medicine
Stock and Other Ownership Interests - Roche/Genentech
 
Amaya Gasco Hernandez
Employment - Foundation Medicine; Kura Oncology
Leadership - Foundation Medicine; Kura Oncology
Stock and Other Ownership Interests - AstraZeneca; Kura Oncology; Roche
 
S. Ivy
No Relationships to Disclose
 
Eliezer Van Allen
Stock and Other Ownership Interests - ervaxx; Genome Medical; Genomic Life; Manifold Bio; Microsoft; Monte Rosa Therapeutics; Riva Therapeutics; Serinus Bio; Syapse; Tango Therapeutics
Consulting or Advisory Role - ervaxx; Genome Medical; Genomic Life; Illumina; Janssen; Manifold Bio; Monte Rosa Therapeutics; Novartis; Riva Therapeutics; Serinus Bio; Syapse; Tango Therapeutics; Tracer Bio
Speakers' Bureau - Illumina; TD Cowen
Research Funding - Bristol-Myers Squibb; Nextpoint (Inst); Novartis; Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Patent on clinical interpretation algorithms using cancer molecular data (Inst); Patent on discovery of chromatin regulators as biomarkers of response to cancer immunotherapy (Inst); Patent on discovery of retained intron as source of cancer neoantigens (Inst)
Travel, Accommodations, Expenses - Roche/Genentech
 
Bose Kochupurakkal
No Relationships to Disclose
 
Geoffrey Shapiro
Consulting or Advisory Role - Bicycle Therapeutics; Merck Serono; Xinthera
Research Funding - Bristol-Myers Squibb/Medarex (Inst); Lilly (Inst); Merck (Inst); Merck Serono (Inst); Pfizer (Inst); Tango Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Patent # 10,934,593 B2 Compositions and methods for predicting response and resistance to CDK4/6 inhibition; Patent #: 9872874 Title: Dosage regimen for sapacitabine and seliciclib Issue Date: 1/23/2018